The role of microRNAs in arterial remodelling

Thrombosis and Haemostasis - Tập 107 Số 04 - Trang 611-618 - 2012
Maliheh Nazari-Jahantigh1, Yuanyuan Wei, Andreas Schober2
1Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Pauwelsstr. 30, 52074 Aachen, Germany
2Uniklinikum Aachen

Tóm tắt

SummaryAdaptive alterations of the vessel wall architecture, called vascular remodelling, can be found in arterial hypertension, during the formation of aneurysms, in restenosis after vascular interventions, and in atherosclerosis. MicroRNAs (miR) critically affect the main cellular players in arterial remodelling and may either promote or inhibit the structural changes in the vessel wall. They regulate the phenotype of smooth muscle cells (SMCs) and control the inflammatory response in endothelial cells and macrophages. In SMCs, different sets of miRs induce either a synthetic or contractile phenotype, respectively. The conversion into a synthetic SMC phenotype is a crucial event in arterial remodelling. Therefore, reprogramming of the SMC phenotype by miR targeting can modulate the remodelling process. Furthermore, the effects of stimuli that induce remodelling, such as shear stress, angiotensin II, oxidised low-density lipoprotein, or apoptosis, on endothelial cells are mediated by miRs. The endothelial cell-specific miR-126, for example, is transferred in microvesicles from apoptotic endothelial cells and plays a protective role in atherogenesis. The inflammatory response of the innate immune system, especially through macrophages, promotes arterial remodelling. miR-155 induces the expression of inflammatory cytokines, whereas miR-146a and miR-147 are involved in the resolution phase of inflammation. However, in vivo data on the role of miRs in vascular remodelling are still scarce, which are required to test the therapeutic potential of the available, highly effective miR inhibitors.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM199405193302008

Schober, 2007, Thromb Haemost, 97, 730, 10.1160/TH07-02-0085

10.1038/nrg2936

10.1038/nature09783

10.1093/cvr/cvn151

10.1152/physrev.00041.2003

10.1161/ATVBAHA.107.159327

10.1161/ATVBAHA.110.221135

10.1161/ATVBAHA.109.200873

10.1371/journal.pone.0018869

10.1161/CIRCRESAHA.109.197517

Cordes, 2009, Nature, 460, 705, 10.1038/nature08195

10.1016/j.atherosclerosis.2011.09.004

10.1101/gad.1842409

10.1038/cdd.2009.153

10.1172/JCI38864

10.1161/ATVBAHA.111.233585

Hergenreider, 2011, Circulation, 124, A11676

10.1089/scd.2010.0283

10.1002/jcp.22230

10.1161/ATVBAHA.110.218149

10.1161/CIRCRESAHA.111.240150

10.1002/jcp.22422

10.1038/embor.2010.172

Yang G, Pei Y, Cao Q, et al. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells. J Cell Physiol 2011; epub ahead of print.

10.1161/CIRCRESAHA.106.141986

10.1038/nature07086

10.1161/CIRCRESAHA.108.185363

10.1074/jbc.M808788200

10.1038/emboj.2009.370

10.1074/jbc.M111.261065

10.1073/pnas.0707493105

10.1016/j.devcel.2008.07.002

10.1038/nature08889

10.1161/ATVBAHA.110.211706

10.1016/j.devcel.2008.07.008

10.1006/jmcc.2001.1419

10.1126/scisignal.2000610

10.1161/CIRCRESAHA.110.226357

10.1161/CIRCRESAHA.109.215566

10.1161/CIRCULATIONAHA.111.037572

10.1093/cvr/cvr227

10.1016/j.jacc.2007.02.059

10.1073/pnas.1002120107

10.1073/pnas.0914882107

10.1016/j.bbrc.2010.02.045

10.1152/ajpheart.00829.2010

10.1073/pnas.1107052108

10.1161/CIRCULATIONAHA.110.005108

10.1016/j.atherosclerosis.2010.12.024

10.1074/jbc.M701050200

10.1016/j.bbrc.2011.05.118

Savoia, 2006, Curr Opin Nephrol Hypertens, 15, 152

10.1111/j.1600-065X.2007.00554.x

10.1089/ars.2005.7.1249

10.1038/nri2708

10.1016/j.febslet.2011.02.009

10.1093/cvr/cvp121

10.1073/pnas.0605298103

10.1074/jbc.M109.056317

10.1016/j.atherosclerosis.2011.07.020

10.1073/pnas.0901216106

10.1016/j.bbrc.2010.03.075

10.1073/pnas.0610731104

10.1074/jbc.M110.102111

Huang, 2010, J Investig Med, 58, 961, 10.2310/JIM.0b013e3181ff46d7

10.1074/jbc.M209634200

10.1073/pnas.0811073106

10.1096/fj.09-131342

10.1073/pnas.0902636106

10.1016/j.immuni.2009.06.024

10.1074/jbc.M110.169367

10.1074/jbc.M110.146852

10.1074/jbc.M109.051235

10.1016/j.molcel.2010.06.010

10.1161/01.ATV.0000254674.47693.e8

10.1002/emmm.201100191

Thông tin
Thông tin xuất bản

Thrombosis and Haemostasis

Tập 107 Số 04

611-618

Thông tin tác giả